Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. - Wikidata - awgldk - TriplyDB

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

http://www.wikidata.org/entity/Q48112332

about

Neurodegeneration in multiple sclerosis: novel treatment strategies Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond The role of neurotrophins in multiple sclerosis-pathological and clinical implications Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Promoting remyelination in multiple sclerosis-recent advances Alemtuzumab for Multiple Sclerosis.Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis Multiple Sclerosis and T Lymphocytes: An Entangled Story Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.Multiple sclerosis: overview of disease-modifying agents ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis.Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.Current and future therapies for multiple sclerosis.Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.Immune cell trafficking from the brain maintains CNS immune tolerance.Alemtuzumab in the treatment of multiple sclerosis.A critical appraisal of treatment decisions in multiple sclerosis--old versus new.Treatment of multiple sclerosis: current concepts and future perspectives.Dendritic cells and multiple sclerosis: disease, tolerance and therapy.Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models.Oligodendroglia and neurotrophic factors in neurodegeneration.Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis.Biotherapeutics for the treatment of multiple sclerosis: hopes and hazards.Disease modification in multiple sclerosis: an update.Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis.Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis.Drug safety evaluation of alemtuzumab for multiple sclerosis.Remyelinating strategies in multiple sclerosis.Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Alemtuzumab in multiple sclerosis: an update.Regulation of human glia by multiple sclerosis disease modifying therapies.Neurons and T cells: Understanding this interaction for inflammatory neurological diseases.

P2860

Q22241472-E4C95957-1AA5-4F95-B11C-A30FD73B0F1A Q26783585-2C816626-6B64-473B-A21E-D215EA2A7733 Q26800128-CA767A17-0E7E-4658-B150-9E116F8B4350 Q26849274-4A3221A4-EF20-44E3-94AE-3A3393C35F86 Q26999417-C6BA86F6-A653-48E9-836E-14990D4F9323 Q27010398-E8CE01A9-9C66-471D-9D23-B3C0A1C41EA3 Q28069730-7433AB89-F856-4EA1-81EA-CFE1F4C542DB Q28081636-C9640D0E-3989-46DA-9E7F-BF6D5C46666B Q28086853-62E5E170-02AD-482F-80F5-37A3379F1BD5 Q28260587-DF698DF5-A770-4C75-A9B6-7F47E88D48EB Q30458930-47376F35-1588-4B8B-BB57-1D2138CC00A2 Q30808014-8AA33A10-2C8D-4880-9E68-06014214CF47 Q33412834-B446C28F-7D53-4403-A594-6E9F26983CCF Q34330211-3965AACD-A0CA-45BE-9375-B758C3C6009F Q34342662-19548F51-42FA-4F36-876A-E698EFC2C40D Q35953466-EF85CEB9-3008-424A-AA54-B95A6EBAC969 Q35959784-3BAD0894-D317-46C6-A10E-BD69F2694CA2 Q36283207-CEC8AC3C-A15F-4BE0-B76F-18C7DF5841CB Q37124529-0AE939D8-C4DB-4899-99CA-2D7A5A4C2732 Q37287769-02A49AD9-605C-4C7D-ADA7-423122840EA1 Q37360536-0CBDD6E4-0A1D-4820-971C-E8B651967C89 Q37602206-D20DE3EE-9CF9-4A2E-BDD1-0DBC3F7E5BA3 Q37649028-388F21C5-5B6F-408D-927F-CB7719DC11DE Q37862062-B2AF312E-00E4-4B41-B387-460195BB61EA Q37884434-7189DA0D-FE76-496D-A4F9-97EF91B837AA Q38070093-23ADAD8C-978A-434E-AB19-27E7AEC92A1B Q38071242-6D6E5A95-4AA0-4232-B4B6-E99AEB0184F7 Q38096248-0FEC2AE2-1461-4879-A32B-C684ED28933D Q38114422-148DF994-A60E-4E7F-B8B3-C1B5ECDF8C17 Q38116451-C022B009-F59D-46D9-B14D-43363A899E56 Q38150823-C9CB10ED-1E3D-4A2F-A8C8-A76E63FCA862 Q38173374-DCBAEF3F-1EF2-4D99-9A3A-5C70670B29EE Q38194115-794F7085-4BB0-46CF-8E00-540EFFD39055 Q38220740-22407209-863B-443A-88B1-F4D8326AF902 Q38261543-75E807A1-8F2C-4293-AF59-F44CC2BDDD37 Q38262622-2ABED689-5F41-4D9E-98E7-A1C645A78467 Q38364547-BEBB3826-AB5F-492D-8BCE-8DEBA36789F3 Q38536770-EF9D8C83-1459-47A5-87F1-519B9F1824B7 Q38563863-647D0F92-77F3-4506-99BE-6F2DA92E7B6D Q38582200-1B0201A3-E281-46DE-9758-0A539A67FE7F

P2860

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

http://www.wikidata.org/entity/Q48112332

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Improvement in disability afte ...... neuroprotective autoimmunity.

@en

Improvement in disability afte ...... neuroprotective autoimmunity.

@nl

type

label

Improvement in disability afte ...... neuroprotective autoimmunity.

@en

Improvement in disability afte ...... neuroprotective autoimmunity.

@nl

prefLabel

Improvement in disability afte ...... neuroprotective autoimmunity.

@en

Improvement in disability afte ...... neuroprotective autoimmunity.

@nl

P1433

Q48112332-A5032303-54F3-46D3-83A5-DDED08CA2245

P1476

Q48112332-2505950F-E34E-4F99-8A7E-E3BC85B47245

P2093

Q48112332-0A14D6DB-7F75-484A-BE3C-D4EFA6C1D362

Q48112332-0F9ED323-3E98-41B7-A94C-B598B04BF868

Q48112332-4ACF0D48-FBED-4579-8EB5-779C4CF8A973

Q48112332-4C0B6BF9-6F15-42DB-82B7-8CDCCC491073

Q48112332-53EB77F9-CB41-4B9C-906B-3F28DF2A5B91

Q48112332-6D5A5B0A-F79F-450E-937D-7B0B39602747

Q48112332-B690A6D5-06DA-4AFC-BCBB-FCF13FA03FAD

Q48112332-C5045522-2ECE-4775-AD5E-E10FEB592BB7

Q48112332-C6896BF4-CB11-4D6C-8C60-5D4D19DCE7D8

Q48112332-DD4CC83D-ADC5-409E-BBBC-3057486E7CD7

P2860

Q48112332-0B995865-A7B5-42C9-861F-397248B7EF57

Q48112332-17E8999A-9A47-4AA7-92F5-D56BD86201C9

Q48112332-19355C76-E27D-448F-BA0E-6B3D166C71C4

Q48112332-1EC4E822-9737-4012-9947-150765F60679

Q48112332-2A63D9CA-942E-4345-84F4-ABB1AB940A39

Q48112332-2B206945-ADAD-44C5-99E1-06D38C973D78

Q48112332-31190267-E365-4E0F-B9C3-AAF09E06FED8

Q48112332-3E577676-355A-436F-8875-DF4B3FE9DEB4

Q48112332-44076761-2A4E-4FE8-BAED-CB403F0E340E

Q48112332-56A62C03-6F56-4944-9D44-6E577CD00835

P304

Q48112332-4F26697E-339A-48EB-A41C-2CDFCFF2374B

P31

Q48112332-F1596933-0B08-4897-8B1C-0DF15DF36B54

P356

Q48112332-75FD653F-552D-4229-8A2C-BB0FBD210795

P407

Q48112332-7DAF9884-22B0-4A41-96CF-5B8B4B9C1195

P433

Q48112332-F45EB9A5-EC7F-4845-A634-33A0EE70C76B

P478

Q48112332-1C02A831-CB5B-42C0-B549-78885A2B2F0C

P577

Q48112332-72BAD8C3-D9D4-4FAE-9323-404DCAB28FF4

P5875

Q48112332-981A8059-6E07-4CCE-AC13-91D4F9DD67EA

P698

Q48112332-A6C396EE-DA95-4EB8-B647-703D73765F72

P921

Q48112332-D94BD5D2-72E7-4C88-9C0F-56E19EBB43E9

P356

P1433

P1476

Improvement in disability afte ...... neuroprotective autoimmunity.

@en

P2093

Alasdair J Coles

http://www.w3.org/2001/XMLSchema#string

Alastair Wilkins

http://www.w3.org/2001/XMLSchema#string

Chia-Ling Phuah

http://www.w3.org/2001/XMLSchema#string

D Alastair Compston

http://www.w3.org/2001/XMLSchema#string

Daniel J Webber

http://www.w3.org/2001/XMLSchema#string

David Margolin

http://www.w3.org/2001/XMLSchema#string

Edward J Fox

http://www.w3.org/2001/XMLSchema#string

Jane M Anderson

http://www.w3.org/2001/XMLSchema#string

Jeffrey Palmer

http://www.w3.org/2001/XMLSchema#string

Joanne L Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system.

Multiple sclerosis

Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

FGF modulates the PDGF-driven pathway of oligodendrocyte development.

The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice

Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy.

P304

2232-2247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWQ176

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 8

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45365561

http://www.w3.org/2001/XMLSchema#string

P698

20659956

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis